Recent studies examine the burden of CRSwNP, looking at quality of life in patients and caregivers and assessing how CRSwNP ...

Vasomotor rhinitis is a cause of runny nose and congestion not related to allergies or an infection. Learn about the symptoms ...

In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic ...

Tezepelumab reduced the size of nasal polyps and the severity of nasal congestion in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps, in a placebo-controlled study.

Silent rhinovirus infection was associated with increased Th2 inflammation levels in the control group and reduced Th2 inflammation levels in the CRSwNP group. Silent rhinovirus (RV) infection is ...

Chronic sinusitis with nasal polyps (CRSwNP) accounts for 20 to 33 percent of these cases. Even after surgical treatment, the recurrence rate of CRSwNP remains high, ranging from 20 to 60 percent ...

An asthma drug has shown positive results when used to treat nasal polyps, researchers have said. Tezepelumab was first approved for treating asthma in 2021, but new research led by a University of ...

Some people require surgery if recurrent sinus infections are caused by severe structural problems or nasal polyps. Endoscopic surgery may also be needed for fungal sinus infections. See a healthcare ...

The proposed uses include an add-on maintenance treatment for asthma in patients aged 12 and older with type 2 inflammation and an eosinophilic phenotype, and as an add-on therapy for adults with ...

Amgen and AstraZeneca have reported complete outcomes from the registrational Phase III WAYPOINT trial of Tezspire (tezepelumab-ekko) for treating chronic rhinosinusitis with nasal polyps (CRSwNP).

Depemokimab is intended for treating chronic rhinosinusitis with nasal polyps. Credit: OleksSH / Shutterstock. UK-based pharmaceutical company GSK has reported positive outcomes from two Phase III ...